J&J To Be Sole Responsible In Talc Punitive Damages Trial
J&J To Be Sole Responsible In Talc Punitive Damages Trial

Introduction
Johnson & Johnson (J&J) will face a new trial on the issue of punitive damages, following the $12 million awarded in compensatory damages to a plaintiff on June 12, who was diagnosed with mesothelioma due to exposure to talcum powder. Recently, Judge Frank Roesch rejected the request from J&J to involve Colgate and Avon in punitive damages.
During a hearing in Oakland, California, the judge set July 8 for the opening argument and rejected J&J's request to wait until it has filed an expedited appeal. Also, the judge rejected J&J's argument that the new jury should be told about the decision from the previous jurors that J&J and Colgate-Palmolive, both were at 40% fault, with the remaining 20% against Avon, which made up the compensatory verdict. The woman's case was given trial preference because she is dying of mesothelioma, and ordered jury selection to begin as soon as possible.
J&J is facing nearly 14,000 talcum powder lawsuits, each raising a common allegation that asbestos exposure from the company’s talc-based products causes ovarian cancer or mesothelioma. Hon. Freda L. Wolfson, U.S.D.J., and Hon. Lois H. Goodman, U.S.M.J., is presiding over all J&J's talcum powder multidistrict litigation (MDL No. 2738; In Re: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices, and Products Liability Litigation) in the District of New Jersey.
Latest News
Talcum Powder Cancer Settlement Talks Begin Sept. 4
Representatives of Johnson & Johnson (J&J) and attorneys for tens of thousands of plaintiffs involved in talcum powder lawsuits are scheduled to meet in September 2025 in an…
Tepezza Hearing Loss Trials Delayed Until Aug 2026
A series of Tepezza hearing loss lawsuits, which were expected to go before juries next year, will now be delayed. The U.S. District Judge overseeing the multidistrict…
Cencora Directors Settle Opioid Oversight Case for $111M
Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids…